Best Life Sciences Companies in Pudong, China
The 44 best Life Sciences companies in Pudong, China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: HaiHe Biopharma.
Our analysis of 50 Life Sciences companies
$5.7b in tracked funding; 40% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Pudong
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | HaiHe Biopharma Developer of reformulations for cancer treatment | $333M | 48 mo ago | Series B | 181 | Ruiping Dong CEO | 90 patents Small-molecule inhibitors for oncology targets (PARP1, AR, MAT2A, SOS1, ENPP1) and formulations | — |
| 2 | Elpiscience Developer of checkpoint inhibitors for the treatment of cancer | $260M | 63 mo ago | Series C | 150 | — | — | — |
| 3 | Singlera Genomics Developer of the NGS-based platform to detect cancer 72Moat top 21%Funding top 26%Market top 30%Patents top 33% All 6 signals ▾Moattop 21% Fundingtop 26% Markettop 30% Patentstop 33% Innovationtop 41% Globalbottom 40% Moat: Editorial + unicorn rating 8/10 · IP moat: 29 patents Funding: Raised $209M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $209M | 25 mo ago | Series B | 300 | — | 29 patents Liquid biopsy DNA methylation biomarkers for cancer detection and tumor assessment | — |
| 4 | Siwei Biotechnology Developer of nanocarrier delivery platform for mRNA vaccines | $206M | 62 mo ago | Deadpooled | — | Li Hangwen Founder | — | — |
| 5 | OriCell Therapeutics Developer of immuno-therapeutics for cancer treatment 72Funding top 16%Patents top 27%Moat top 28%Innovation top 34% All 8 signals ▾Fundingtop 16% Patentstop 27% Moattop 28% Innovationtop 34% Newstop 36% Markettop 37% Talentbottom 49% Globalbottom 43% Funding: Raised $170M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Patents: 56 patents matched (strict assignee match) · 55 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $170M | 4 mo ago | Series D | 150 | He Xiaowen Co-Founder | 56 patents Patents concentrated in health & consumer products | — |
| 6 | GenFleet Therapeutics Developer of drugs for treating tumors and autoimmune diseases | $166M | 55 mo ago | Public | — | Jiong Lan Co-Founder & CEO | 210 patents Design and synthesis of small‑molecule and macrocyclic oncology drugs and antibody‑drug conjugates | — |
| 7 | MicroPort CardioFlow Medtech Corporation Developer of smart medical devices for patients with heart valve diseases | $132M | 76 mo ago | Public | 200 | — | 280 patents Design and delivery of balloon catheters and stent deployment systems. | — |
| 8 | Duality Biologics Developer of ADC therapeutics to treat cancer and autoimmune diseases | $120M | 63 mo ago | Public | — | John Zhu Founder&Ceo | 136 patents Targeted antibody-drug conjugates and bispecific antibodies with novel linker chemistries | — |
| 9 | Phrontline Biopharma Developer of therapeutics for various diseases 64Talent top 28%Funding top 29%Global bottom 48% All 3 signals ▾Talenttop 28% Fundingtop 29% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $60.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $60M | 9 mo ago | Seed | — | Siyi Hu Co-Founder | — | — |
| 10 | NUTSHELL Developer of small molecule-based therapeutic solutions for the treatment of cancer | $60M | 53 mo ago | Series A | — | Zhengtian Yu Co-Founder & CTO | — | — |
| 11 | Hrain Biotechnology Developer of tumor immunotherapy technology | $57M | 64 mo ago | Deadpooled | 260 | — | 21 patents Therapeutic nanobody/antibody engineering for cancer immunotherapy targets (CD70, MSLN, Trop2) and viral detection methods. | — |
| 12 | ABM Developer of small molecules therapeutics to treat cancer | $50M | 55 mo ago | Series B | — | Chen Chen Co-Founder & CEO | — | — |
| 13 | Zhengxu Biotechnology Developer of gene-editing technology to treat genetic diseases | $47M | 57 mo ago | Series C | — | Chen Jia Founder | — | — |
| 14 | VivaVision Biotech Developer of therapeutic solutions for treating multiple eye diseases | $46M | 32 mo ago | Series E | — | Shen Wang Founder & CEO | — | — |
| 15 | neoX Biotech Provider of research and characterization of protein-protein interactions to facilitate drug discovery | $40M | 61 mo ago | Series A | 70 | Fan Liu Co-Founder | — | — |
| 16 | Kangpu Developer of small molecule drugs to treat cancer, auto-immune, and inflammatory disease | $39M | 63 mo ago | Series B | 25 | Chuansheng Ge Co-Founder & CEO | — | — |
| 17 | ITabMed Developer of immunotherapeutics to treat cancer | $20M | 56 mo ago | Series A | — | Xiaoqiang Yan CEO | 5 patents Bispecific antibody therapeutics targeting CD19 and CD3 for cancer immunotherapy | — |
| 18 | Huida Developer of gene therapies for the treatment of multiple disease conditions | $19M | 51 mo ago | Series C | 150 | Shi Linyu Co-Founder | 2 patents Water pipeline freeze protection and secure fastening hardware | — |
| 19 | Shanghai Baixin'an Biotechnology Developer of coronary stent system | $16M | 81 mo ago | Public | 58 | — | — | — |
| 20 | Shanghai Maibang Biotechnology Developer of animal cell culture media | $16M | 52 mo ago | Series B | — | Max Wang Co-Founder & Co-CEO | — | — |
| 21 | REMD Provider of steep pulse treatment device for prostate cancer | $15M | 59 mo ago | Series A | 100 | — | — | — |
| 22 | Nk-Celltech Provider of immuno-oncologic drugs for cancer 40Market top 45%Funding top 46%Global bottom 38% All 3 signals ▾Markettop 45% Fundingtop 46% Globalbottom 38% Market: 60 employees (top 31% of Life Sciences) Funding: Raised $14.9M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $15M | 13 mo ago | Series A | 60 | — | — | — |
| 23 | Shenqi Medical Developer of a medical device for cardiovascular surgeries | $14M | 72 mo ago | Series C | — | Dai Zhihao Founder | — | — |
| 24 | Shanghai OPM Biosciences Antibody culture media and vaccine culture products developer | $14M | 72 mo ago | Series B | 261 | — | — | — |
| 25 | Zedman Pharmaceuticals Developer of drugs for the treatment of autoimmune inflammatory diseases | $14M | 22 mo ago | Series A | — | Chen Genghui CEO | — | — |
| 26 | Milestone Biotechnologies Company solutions for various applications including single-cell mutation analysis, CDMO services and… 24Funding top 44%Talent bottom 49%Market bottom 37%Global bottom 36% All 4 signals ▾Fundingtop 44% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $13.6M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 24/100 | $14M | 19 mo ago | Series A | — | Zhang Jinbao Founder & CEO | — | — |
Top 12 Life Sciences companies in Pudong
#1
Series D · Pudong, Shanghai · founded 2015 · 150 employees$170Mraised▾
Developer of immuno-therapeutics for cancer treatment. It offers CAR-T- based therapies and antibodies for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, non-small cell lung cancer, and others.
- Apr 2026Series D$110M
- Jan 2026Series C$70M
- Feb 2023Series B$45M
- Aug 2022Series B$125M
#2
Seed · Pudong, Shanghai · founded 2022$60Mraised▾
Developer of therapeutics for various diseases. It offers a proprietary dual linker payload ADCs that are delivered to and concentrated in the tumor microenvironment, and bispecific dual payload ADCs that have the benefits of dual targeting that dilever two different MOA of payloads to cancel cells simultaneously.
- Nov 2025Seed$60M
#3
Series A · Pudong, Shanghai · founded 2020 · 60 employees$14.9Mraised▾
Provider of NK cell therapy for treating cancer, cellular drugs to precisely target of tumors and tumor immune microenvironment (TIME)
- Jul 2025Series A$13.9M
- Jul 2022Series A$14.9M
#4
Series B · Pudong, Shanghai · founded 2014 · 300 employees$208.6Mraised▾
Developer of the NGS-based platform to detect cancer. The company has methylation haplotyping technology for detecting cancer biomarkers. Tumor cells release circulating tumor DNA (ctDNA) into the blood when undergoing apoptosis or necrosis and this ctDNA is detected as cancer biomarkers. The company has developed a PanSeer assay that measures distinct tumor-specific methylation patterns in adjacent methylation sites. It can detect cancer up to four years before conventional diagnosis.
- Jul 2024Series B$13.8M
- Jun 2022Series B$44.9M
- Dec 2020Series B$150M
- 2018Series A—
#5
Series A · Pudong, Shanghai · founded 2014$13.6Mraised▾
Company solutions for various applications including single-cell mutation analysis, CDMO services and agriculture. It specializes in the production and supply of various biological products, including single-cell mutation analysis, PBMC and immune cell subtypes, animal liver cells, and in vivo and in vitro drug efficacy.
- Jan 2025Series A$13.6M
- Aug 2023Series A—
#6
Series A · Pudong, Shanghai · founded 2021$14Mraised▾
Developer of drugs for the treatment of autoimmune inflammatory diseases. The company focuses on the development and clinical research of therapeutic drugs for multiple autoimmune inflammatory diseases related to the aryl hydrocarbon receptor (AhR) target.
- Oct 2024Series A$14M
#7
Series B · Pudong, Shanghai · founded 2012 · 181 employees$332.7Mraised▾
Developer of reformulations for cancer treatment. The company's lead product candidate Liporaxel is used as an oral formulation for the treatment of cancer. Other products of the company include ON101 used for reducing wound inflammation, Lucitanib used for the treatment of cancer, etc.
- Jul 2022Series B$14.8M
- Jul 2020Series B$171.3M
- Feb 2019Series A$146.6M
#8
Series E · Pudong, Shanghai · founded 2016$46Mraised▾
Developer of therapeutic solutions for treating multiple eye diseases. The company has developed a drug candidate VVN001 that helps in treating dry eye diseases such as e dryness, foreign body sensation, burning, itching, photophobia, jealousy, and blurred vision. Other products include VVN349 for atopic dermatitis, VVN460 for psoriasis, VVN539 for glaucoma, and many more.
- Dec 2023Series E—
- Apr 2021Series D$46M
#9
Series C · Pudong, Shanghai · founded 2017 · 150 employees$260Mraised▾
Elpiscience is developing immunotherapies for cancer. The company has its pipeline which includes in-house and partnership projects. The lead candidate, ES 101 is a bispecific antibody targeting 4-1BB and PD-L1 (preclinical stage). The molecule is developed by Inhibrx and the company has Chinese rights. Another candidate, ES001 is an anti-TIM-3 antibody, developed by Enumeral.
- May 2021Series C$105M
- Dec 2019Series B$100M
- Dec 2018Series A$35M
- 2017Series A$20M
#10
Public · Pudong, Shanghai · founded 2017$166.1Mraised▾
Developer of drugs for treating tumors and autoimmune diseases. The company's pipelines started with mediating the tumor microenvironment. The company is involved in the development of new drugs for the new subtypes of tumor mature target families the third type of was the development of new drugs for mature immune targets, including small molecule drugs, and biological macromolecular drugs.
- Dec 2021Series C$75M
- Jan 2021Series B—
- Mar 2020Series B$58M
- Nov 2018Series A$17.3M
#11
Deadpooled · Pudong, Shanghai · founded 2016$206.4Mraised▾
Developer of nanocarrier delivery platform for mRNA vaccines. The LPP/mRNA is a patented nano model for delivering mRNA drugs through two-layer structure technology. The company has developed mRNA-based personalized therapeutics which are delivered through the delivery platform for treating cancer, infectious disease, protein defects diseases, and genetic diseases.
- Jun 2021Series C$188M
- Feb 2020Series A$4.3M
- Aug 2019Series A$14.2M
- Seed—
#12
Public · Pudong, Shanghai · founded 2020$120Mraised▾
Developer of ADC therapeutics to treat cancer and autoimmune diseases. It offers DITAC (Duality Immune Toxin Antibody Conjugate) for solid tumors and DIMAC (Duality Immune Modulating Antibody Conjugate) for auto-immune disorders.
- May 2021Series B$90M
- Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in China
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 5,865 China-affiliated papers.
- Chinese Academy of Sciences263
- Chinese Academy of Agricultural Sciences227
- Ministry of Agriculture and Rural Affairs168
- China Agricultural University159
- Huazhong Agricultural University138
- Gene4→218
- Gene knockdown3→73
- Transcriptome1→62
- Detection limit1→59
- Mutant3→56
- Gene9→275
- Gene knockdown1→166
- Downregulation and upregulation2→161
- Apoptosis6→129
- Transcription factor3→77
- Agriculture6→68
- Antibiotic resistance1→43
- Resistance (ecology)2→33
- Gene2→32
- Synthetic biology1→30
Where biotechnology is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in China
China biotechnology patent filing is accelerating — 58,925 filings from 8,000 assignees (2016–2025), led by Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine, UNIV Jiangnan; annual filings 1737→10545.
- Shanghai Hengrui Pharmaceutical1154
- Jiangsu Hengrui Medicine1027
- UNIV Jiangnan1000
- Innovent Biologics Suzhou666
- UNIV Tsinghua627
- Jiangsu Hengrui Pharmaceuticals594
- UNIV Xiamen575
- UNIV Beijing549
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.